• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

    2020-10-22 04:30:58AnujBohraQuratAlAinRizviCharlotteYuenYuKeungAbhinavVasudevanDanielvanLangenberg
    World Journal of Gastroenterology 2020年36期
    關(guān)鍵詞:大伙

    Anuj Bohra, Qurat-Al-Ain Rizvi, Charlotte Yuen Yu Keung, Abhinav Vasudevan, Daniel R van Langenberg

    Abstract

    Key Words: Inflammatory bowel disease; Infliximab; Safety; Cost; Therapy; Drug reaction

    INTRODUCTION

    Infliximab is a biologic monoclonal IgG antibody against tumour necrosis alpha (anti-TNF). It is a highly effective induction and maintenance treatment for multiple immune-mediated inflammatory disorders, including inflammatory bowel diseases (IBD)[1-3]. Recently in Australia and many countries worldwide, the accessibility of infliximab for indications within IBD has increased, alongside an increasing trend to use accelerated doses and shorter dose intervals to regain and/or achieve remission in certain disease subtypes[4,5]. Hence, despite a growing number of biologic options, many of which are subcutaneously administered, there has still been an increased demand for infliximab infusions over recent years. As a maintenance therapy, infliximab (and other infusion-based biologic agents) are often prescribed on a longterm basis[6-8]. Allocation of funding to resource-intensive infusion centres may not always a priority for hospital administrators, given the traditional hospital model of care is typically focussed on acute inpatient care resulting in continual pressure on infusion centres already at, or near capacity. Additionally, the cost of infusion-based treatment is expensive, with some studies suggesting that the cost of the administering infliximab is approximately 9% to 12% of the total cost of treatment[9,10].

    In an effort to address these capacity and cost issues for infusion centres shortening the infusion time is one potential solution. Rapid infliximab infusions (at typically 30-60 min’ duration per infusion) have been previously identified in IBD and other indications as safe, with the potential for increased capacity yet reduce cost, plus apparently improve patient satisfaction[9,11]. Despite this, with the recent further exponential growth of infusion-based therapies for various chronic diseases, improving efficiencies within infusion centres does not appear sufficient and there is still an imperative to explore further alternatives.

    Home-based infusions are therefore a logical extension from hospital or infusioncentre based infusions and are potentially appealing to both patients and health providers. Home-based infusions of many drug therapies have been demonstrated to be cost-saving and are used in many jurisdictions worldwide[12,13]. However, homebased infliximab poses a challenge given the relatively high rate of infusion reactions, including anaphylaxis and anaphylactoid reactions[14,15], the need to dilute and refrigerate the medication and the two hours required for the infusion and one hour observation period thereafter[16]. Some of these problems can be overcome to allow patients to have their infusions at home. For example, initial therapy can be completed in the hospital to monitor for any reactions and then subsequent infusions can be administered at home. Rapid infusions and home-based infusions of infliximab are currently undertaken at our hospital. The safety of this approach is yet to be comprehensively evaluated. Therefore, we aimed to evaluate the safety of transition from standard hospital-based infliximab infusions to rapid infusions and thence to home-based infusions in a protocolised manner, while also assessing efficiency, cost savings and patient satisfaction with this process.

    MATERIALS AND METHODS

    Patient selection and data collection

    All consecutive patients with confirmed IBD attending two Australian tertiary inflammatory bowel disease centres over a 12-year period from January 2005 to March 2017 who were prescribed infliximab and commenced infusions at the study centres were identifiedviaan IBD database and/or pharmacy dispensing records, then prospectively followed. Inpatients receiving infliximab (for example for acute severe colitis) were excluded from this analysis. All patients underwent standard dosing of infliximab 5 mg per kilogram of body weight for induction at week 0, 2 and 6 followed by maintenance infusions, where dosing/dosage interval may have been altered as per the treating clinician’s discretion, predominantly to address secondary loss of response.

    Data including baseline demographic data, IBD data including disease distribution duration and complications, therapeutic data including adverse drug reactions (ADRs) and location of infliximab administration, were extracted from medical records. The severity of infliximab infusion reactions were graded retrospectively according to the Common Toxicity Criteria (CTC) version 2.0[17]from 1 to 4, with a CTC score of 1-2 graded arbitrarily defined as “mild” and 3-4 as “severe” reactions respectively.

    Inclusion criteria:(1) Aged 18 and above; and (2) Received maintenance therapy infliximab between January 2005 and March 2017 for an IBD indication.

    Exclusion criteria:(1) Less than age 18; (2) Received infliximab for a non – IBD indication; and (3) received infliximab as an inpatient.

    Study outcome measures

    The primary outcome measure in this study was the safety of infliximab infusions, with the standard infusion protocol as per manufacturer’s guidelines as the reference, compared to (1) a rapid infusion protocol; and (2) a rapid infusion protocol administeredviaa home-based service, comparing relative incidence of serious adverse events. Secondary outcomes assessed included the relative cost of infusion centre and home-based infliximab infusions and factors associated with a higher risk of infusion reactions in order to risk stratify patients prior to referral for home-based infusions.

    Initial standard 2-h infusion data was available from patients infused between January 1, 2005 to December 31, 2013, inclusive. Rapid 30-min infliximab infusion data was available from patients infused between January 1, 2014 and March 31, 2017 inclusive and home-based rapid infliximab infusion data was available from patients infused between October 1, 2017 and December 31, 2019 inclusive. In each case, needle to departure times were collected for each patient for time spent in at an infusion centre and compared between the standard and rapid infusion groups.

    Cost analysis

    Moreover, a cost analysis was performed for infusion centre and home-based delivery of infliximab, comprising study centre staff costs (per unit time) and infusion-related consumables (per unit), per infusion. Total infusion time duration was measured from time of cannula insertion to the patient’s time of departure from the infusion centre, or the time of the nurse’s departure from the home setting (i.e., needle to departure time), given these events were accurately recorded in the medical records for all patients.

    Satisfaction and productivity survey relating to rapid/ home-based infusions

    Patients who were transitioned to home-based infusions were asked to complete a survey comprising items assessing their satisfaction regarding rapid infusions compared to standard infusions and rapid infusions administered in infusion centrebasedvshome-based settings (see Appendix). The items included were customised based on feedbackviaqualitative interviews of a subgroup of rapid infusion patients (by investigators DvL and QaR), given no suitable, previously validated surveys were found in the literature. Responses to each item were recorded across a numerical scale from 1 (most negative) to 5 (most positive) with 3 denoted as neutral. Furthermore, the short IBD Questionnaire (sIBDQ), to measure concurrent health-related quality of life and the Work Productivity and Activity Impairment in IBD Questionnaire (WPAIIBD) were also administered to examine perceived effects of rapid infliximab infusions (including home-based) on these domains[18]. Based on the cut-off derived by Swartet al[19], a sIBDQ score of greater than 55 (total 70 indicating excellent quality of life) was deemed to represent a “satisfactory/normal” quality of life[19,20]. Loss of work productivity and daily activity impairment (expressed as a percentage, 100% indicating complete loss/impairment) were derived from the WPAI-IBD as per Reillyet al[20]. The surveys were applied to a seven-day period including a home-based infliximab infusion.

    Infliximab infusion protocols used

    The rapid infusion protocol as applied is shown in Figure 1. Patients underwent their first 3 infusionsviaa standard 2-h infusion protocol, then progressed onto an “accelerated” 1-h infusion for infusion 4-6 if there were no adverse reactions and from the 7thinfusion onwards then received “rapid” infusions over 30 min thereafter assuming no further reactions. ADRs were treated immediately according to severity and only those graded as mild-moderate had a subsequent re-trial of infliximab at the last tolerated infusion rate. A standardised pre-medication regimen of 200 mg intravenous hydrocortisone, 10 mg oral cetirizine and 1 g oral paracetamol was administered to all patients prior to their first three standard infusions and also immediately in the case of ADRs, as per the nursing and/or medical staff’s discretion at the time.

    Subsequently, those who tolerated at least three rapid infusions without ADRs were offered the opportunity to transition their infusion to home-based infusions. Patients with known active psychiatric comorbidities, unsafe (i.e., for visiting nursing staff) or itinerant living conditions and/or previous poor adherence to medications, infusion and/or clinic visits were deemed unsuitable candidates for home-based infusions and were not offered this option.

    Ethics approval

    The Eastern Health Human Research Ethics Committee approved the study as a low risk audit (LR 64/2017), thus informed consent was deemed not required.

    Statistical analysis

    Figure 1 Rapid infliximab infusion protocol. BP: Blood pressure; IV: Intravenous; IFX: Infliximab.

    Comparisons between the infusion groups were performed using non-parametric statistics (assuming non-normal distributions) with medians (ranges) presented and Mann-Whitney tests calculated where appropriate. Proportions were expressed as percentages and compared using Fisher exact tests, including relative risks (RR) of infusion reactions/ADRs which were presented for both per infusion and per patient.

    In order to determine factors potentially associated with the occurrence of one or more infusion reaction(s) to rapid infliximab infusion(s), univariable analyses [expressed as odds ratios (OR) for categorical variables, with 95% confidence intervals displayed] were performed. Then a multivariable logistic regression analysis was conducted with the occurrence of an infusion reaction(s) due to rapid infusion as the dependent variable. Multiple exploratory models were initially undertaken and forced entry models were always used, with the final model chosen on the basis of effect size and goodness of fit of the overall model. All variables with significant or those trending to significance were included in the multivariable analysis plus other putatively important factors were included, such as age and body mass index (BMI) (dichotomised by cut-off < 22 kg/m2representing the lowest quartile in this cohort). Those factors exerting minimal or no effect size within the model (as per standardised B values) were excluded from the final model. APvalue of < 0.05 was deemed to be statistically significant throughout the study.

    RESULTS

    Baseline demographics

    The standard infusion cohort comprised 169 patients who received a total of 2214 infliximab infusions over an 8-year period (2006 to 2013 inclusive) and the rapid infusion cohort comprised 129 patients who received a total of 1461 infusions over a 4-year period (2014-2017 inclusive). Home-based rapid infusions were administered to 32 patients, with a total of 405 infusions over 2.2 years (October 2017 to December 2019 inclusive). The baseline characteristics of the standard and rapid infusion cohorts are represented in Table 1.

    Infliximab infusion ADRs and outcome of rechallenges in standard vs rapid infusion cohorts

    In the standard infusion cohort, a total of 23 patients experienced ADRs directly related to infliximab infusion(s), with 16 of these graded as mild according to CTC. All 16 patients were rechallenged with infliximab of which 15 tolerated the subsequent infusion with the aid of premedications and a slower infusion rate. Seven patients had severe reactions and were not rechallenged.

    In the rapid infusion cohort, 8 patients experienced ADRs due to infliximab, all ofwhich (8/8) were mild as per the CTC. Of these, 7 patients were rechallenged with concurrent premedications administered and all seven tolerated the subsequent infusion; four patients returned to rapid infusions, two remained on accelerated infusions and one returned to the standard infusion protocol. All of the eight patients described had previously documented ADRs to standard protocol infusions.

    Table 1 Baseline characteristics comparing the standard infusion (n = 169) and rapid infusion (n = 129) cohorts

    Hence per infliximab infusion administered, the relative risk (RR) for a mild reaction was 0.8% and 0.7% and for a severe reaction was 0.2% and 0.0% in the standard infusion and rapid infusion cohorts respectively. Per patient, the overall RR for a mild reaction was 10.7% and 7.8% and for a severe reaction 3.0% and 0.0% within the standard and rapid infusion cohorts respectively, as shown in Table 2.

    Moreover, there was a greater likelihood of patients having an infusion reaction (mild or severe) in the standard protocol cohort than patients receiving rapid protocol infusions, RR 3.0, 95%CI (1.2, 7.7),P= 0.02. The median duration from the commencement of infliximab and the first infusion reaction per patient was 17 d (0, 1401) for standard infusions and 637 d (45, 2122) for rapid infusions respectively.

    Factors associated with increased risk of infliximab infusion reactions in this cohort

    A univariable logistic regression analysis was performed on all patients in the cohort who received three or more infliximab infusionsviathe rapid infusion protocol. Factors found to be significantly associated (P< 0.05) and/or trending to significance (0.05 ≤P≤ 0.15) with the occurrence(s) of infliximab ADR/s were then included into a multivariable logistic regression analysis, as shown in Table 3. In summary, a lower BMI (< 22 kg/m2), history of one or more extra intestinal manifestations, longer disease duration (> 3 years) and previous exposure to another biologic were each independently associated with a higher likelihood of infusion reaction(s) to rapid infusions (eachP< 0.05). There was a non-significant trend to a higher risk also with prior episodic and/or a break in maintenance infliximab dosing.

    再說的時候,就說到找一陣了,還是找不到。找不到,摟寶的就直起身,說剛才你們看到了,是萬子吧?他們說,有紅有黑的,應(yīng)該是吧。見大伙認帳,摟寶的跟了句,是八萬吧?這句話,大伙不認帳了。就那么一閃,誰也看不清呀。他想想,也是,那怎么辦呀?大伙說,再找找吧,找到了,我們給錢的,不賴帳的。這次,大伙還幫他找了。找到最后,也沒找到。

    Table 2 Infusion reactions per cohort, type and severity

    Comparison of infusion time/cost and productivity (standard vs rapid infusion cohort)

    Median needle to departure time was significantly higher in the standard protocol than the rapid protocol group [108 (70, 253)vs50 (33, 90) min,P< 0.001] (Figure 2). Based on local costing and consumables, this equated to a median per infusion (per chair) cost of $AUD 49.80 per rapidvs$107.50 per standard protocol infusion (P< 0.001). Hence since inception, rapid infusion protocols resulted in a net cost saving of $AUD 84344 (a net 54% cost reduction) across the whole study centre cohort and follow-up period.

    Transition from infusion centre to home-based rapid infusions: Safety and cost analysis

    The baseline characteristics of the rapid home and rapid infusion centrecohorts are represented in Table 4. 32 patients were transitioned to home-based infusions havingreceived at least three rapid infusions in hospital infusion centres with no history of infusion reaction/s to rapid infusions. In total, 405 infliximab infusions had hitherto been administeredviathe home-based service as of the end of the study follow-up period, with no (0%) reported ADRs. Six patients who subsequently withdrew from the home-based infusion service were due to personal choice (n= 3), change to a different biologic (n= 2) or death (n= 1, unrelated to IBD and/or associated therapies).

    Table 3 Univariable and multivariable logistic regression analyses depicting factors potentially associated with increased likelihood of infliximab infusion reaction/s with a rapid infusion protocol in this cohort (n = 129)

    Table 4 Characteristics of home-based vs infusion centre-based rapid protocol groups

    Moreover, there was no significant difference in needle to departure times between infusion centre and home-based rapid infusions [median 50 (33, 90)vs45 (31, 90) min respectively,P= 0.21] (Figure 2). In turn, there were similar costs (incorporating staffing and consumables) between these groups (median $49.80vs$39.20 per infusion,P= 0.20).

    Figure 2 Needle-to-departure times for standard vs rapid (further subdivided by infusion centre and home based) infliximab protocols.

    Patient satisfaction with home-based infusions: Data from survey

    Of the 32 patients who received infliximabviathe home-based infusion service, 31 (97% response rate) completed the survey as described. 26 of the 31 were in clinical remission as per CDAI < 150 at the time of survey and the median sIBDQ score in responders was 55 (33, 65) with 57% scoring in the “normal” IBD QoL range as per Swartet al[19].

    Only 2 patients (6.4%) reported that their infliximab infusions had a negative impact on their quality of life overall. All 31 (100%) patients preferred the rapid infusionvsthe standard infusion protocol, with 17 patients (54.8%) specifically stating this was due to enhanced convenience (Figure 3).

    14 of the 31 responders (45.2%) disagreed with or were neutral about a preference for home-basedvsinfusion centre-based infusions and 19 (61.3%) found home-based infusions to actually be more inconvenient than those administered in an infusion centre (Figure 3).

    Qualitatively, reasons provided for this included a lack of coordination and communication of the timing of infusions, unforeseen delays in nurse arrival at their home, lack of nursing staff (e.g., due to illness or extra demand) on certain days forcing patients to attend the parent hospital for their infusion(s), lack of sufficiently skilled nurses resulting in difficulties obtaining intravenous access and/or administering infusion at slower rates than prescribed. Additionally, others reported a reluctance to “medicalise” their home and/or have infusions in presence of family members (especially their children) or work colleagues. Also, some patients missed the familiarity of the same nursing staff and the camaraderie enabled by attending the same infusion centre, as many had done, for several years.

    Impact of home-based infusions on work productivity/activity as per survey

    Responses from the WPAI-IBD showed that in the week including when infliximab was infused at home, there was a median of 0 h per week missed from paid work (range 0, 36.7 h), with only 4 (12.9%) reporting a total of one or more hours of work missed in the same week. Also, the median overall work impairment (incorporating both percentage of work hours missed and impairment of work performance) was 10.0% (0, 81.0).

    DISCUSSION

    Figure 3 Results of patient satisfaction survey and preferences regarding standard vs rapid and infusion centre vs home-based infusions.

    This study has demonstrated the safety of rapid 30-min infliximab infusions compared to standard 2-h infusions in patients with IBD. Moreover, by applying a rational stepwise protocol as per Figure 1 culminating in almost 1500 rapid infusions, none of these resulted in severe reactions. Furthermore, of the 8 patients who had mild reaction, 7 were able undertake a re-trial of infliximab on premedication with 6 successfully transitioning back to 30-min rapid infusions. These safety data are consistent with similar protocolised rapid infliximab studies previously[9,21,22], yet are critical to confidently administering infliximab infusions in home-based settings. Otherwise, without stringent protocols, infliximab infusion reactions have been reported in up to 5%-10% of infusions in IBD[15,23], which in our view does not provide adequate assurance of safety for home-based infliximab. Indeed, in this cohort, none of the home-based infusions experienced an adverse reaction as a result of this study centre’s stepwise protocol introducing rapid infusions prior to transitioning to the home.

    In addition, this study is one of the first to elucidate factors associated with a higher risk of adverse reactions with maintenance rapid 30-min infusions, which enables clinicians to further mitigate the risk of adverse reactions on a case-by-case basis. Although infusion reactions to initial infliximab infusions (e.g., with induction or with episodic dosing) are typically attributable to allergic or massive cytokine release pathways, longer term reactions are postulated to be driven primarily by the development of immunogenicity (i.e., antibodies) to infliximab[24]. Accordingly, this study demonstrated that a longer disease duration (> 3 years) was associated with a higher risk of reaction(s), consistent with the known cumulative incidence of antibodies to infliximab in prospective studies[25]. Also, those with prior biologic exposure and/or a break in previous infliximab dosing were found, at least in univariate analysis, to be at higher risk of reaction(s) as has been shown elsewhere[26]. Furthermore, the presence of extraintestinal manifestations, suggestive of a more systemic inflammatory burden and in turn a greater propensity for immunogenicity – for instance due to presence of alternate cytokine-mediated, immune-complex and/or complement mediated processes – appears to be another important risk factor with rapid infusion reactions. Although there was a non-significant trend in univariable analysis to a protective effect of concomitant thiopurine/immunomodulator therapy on infusion reactions, presumably due to their negating effect on antibody development, this did not persist in multivariable analysis. Interestingly, a lower BMI (< 22 kg/m2) was associated with increased risk of rapid infusion reaction(s) despite recent publications showing increased drug clearance and lower anti-TNF drug trough levels seen with higher BMI[27,28]. However, a lower BMI with resultant reduced volume of distribution may in fact result in relatively higher infliximab trough levels and hence greater potential for immunogenicity and thus acute and delayed ADRs. Infliximab drug levels and anti-drug antibodies were not routinely performed in this cohort, so further study into the potential relationship between these factors are needed.

    One of the key benefits of transitioning to 30-min infliximab infusions is that of reduced cost and enhanced productivity for an infusion centre. With introduction of rapid infusions, we demonstrated a halving of needle to departure times per infusion in a real-world context, with attendant cost reduction of 54% across the whole cohort. At an institutional level, this enables a potential doubling of throughput with the same staffing costs for an infusion centre. For the patient and at a societal level, there are additional flow-on benefits such as reduced car parking costs, reduced absence from work and/or family commitments through to improved patient productivity.

    Given the increasing array of intravenous therapies, including infliximab, for chronic diseases leading to infusion centre capacity concerns in many jurisdictions worldwide, transitioning to home-based infusions is a logical solution. However, to ensure the economic sustainability of home-based infusion service, nurses theoretically need to conduct at least 3-4 infusions at patients’ homes per standard 8-h shift, allowing for travel between homes, preparation of infusions and intravenous access, communication with patients,etc. Hence administering infliximab slower than over 30 min is unlikely to be cost-effective in most cases. This study has demonstrated the safe, sustainable administration of infliximab in a home-based setting, subject to appropriate patient selection. Furthermore, this study is one of the first to assess patient satisfaction which overall was high, with 81% highly satisfied or satisfied with home-based infusions. In addition, survey responders reported minimal impact on work or other activitiesviathe WPAI during a typical week that included a homebased infliximab infusion.

    However, the study also revealed previously un-appreciated caveats to implementation of home-based infusions from the patients’ perspective. Almost half of the survey responders were neutral or disagreed that home-based infusions were more convenient, anecdotally for reasons including unforeseen delays to nurse arrival, variable availability of staff to administer infusions, impacts on work and social life and medicalising their home with infusions. These are unintended consequences of transitioning to home-based infusions and pose potential challenges to this model of care which therefore warrant further research and evaluation.

    This study has several limitations, including the retrospective nature of data collection, however the risk of recall bias is somewhat mitigated given this study was primarily an evaluation of protocol and safety in a relatively consistent, homogeneous single centre population. Although the sample size for rapid and standard infusion cohorts were relatively large, the home-based infusion subgroup was small which may have led to selection bias and larger scale evaluation of the latter is required in future. Furthermore, given the large time period across which data was collected and local contemporary practice, we were unable to evaluate the putative relationship between infliximab trough/antibody levels and occurrence of infusion reactions. There was a difference in the rate of psychiatric disorders between the groups. While this is unlikely to have an impact on the results it does reflect that there may be some differences between the groups that was not captured in our demographic data. Prospective validation of the results is required.

    CONCLUSION

    In conclusion, this study comprehensively outlines a safe, patient centred approach to transitioning patients receiving infliximab for IBD from initial standard protocols through to rapid home-based infusions. With careful patient selection, we have demonstrated that the risk of ADRs with home-based infusions is negligible and thus these data are reassuring to patients, clinicians and healthcare providers alike. Whilst there are significant logistical challenges in providing a failsafe, home-based infusion service and ongoing evaluation especially in meeting patient’s care needs is warranted in this regard, most patients were satisfied with this service and the convenience it provides. This study has therefore defined a rigorous framework for the safe, potentially cost saving delivery of not only infliximab but potentially other similar medical infusions at home.

    ARTICLE HIGHLIGHTS

    Research background

    Infliximab is one of the most commonly used biologic therapies in the management of inflammatory bowel disease (IBD). With the development of infliximab biosimilars and resulting reduction in medication cost, its availability and usage worldwide has seen exponential growth for all therapeutic indications.

    Research motivation

    Previous studies have suggested rapid 30 min infliximab infusions to be safe in patients with IBD. Despite this, few centres have moved to deliver infliximab therapy for IBD at a patient’s home and there remains a paucity of literature demonstrating the cost benefit of rapid infliximab infusion compared to standard therapy.

    Research objectives

    The primary aims in this study were to evaluate the safety of transition from standard hospital-based infliximab infusions to rapid infusions and thence to home-based infusions in a protocolised manner, while also assessing efficiency, cost savings and patient satisfaction with this process.

    Research methods

    This retrospective study was conducted across two tertiary IBD centres in Australia. Based on pharmacy prescribing records and historic IBD databases, patients who received infliximab over a 12-year period were identified. Data related to infliximab therapy was retrospectively obtained. Patients that were transitioned to at home infliximab were prospectively surveyed for satisfaction and productivity.

    Research results

    Our study reinforced previous findings in showing that rapid 30 min infliximab was safe in patients IBD with minimal side effects. Furthermore, with careful patient selection patients receiving rapid infusion infliximab were able to be safely transitioned to home based therapy. Rapid infliximab infusions resulted in the halving of time patients spent receiving an infusion and resulted in a 54% reduction in delivery related costs. Patients found the transition to rapid infliximab to be highly satisfying but were neutral about receiving infliximab therapy at home.

    Research conclusions

    In our study, rapid 30 min infliximab infusions appeared to be safe and in a protocolised manner could be delivered safely at home. This process has the ability to substantially reduce costs related to delivery of therapy and provides a viable alternative to under resourced infusion centres in the delivery of infusion therapy.

    Research perspectives

    Rapid Infliximab therapy can be delivered safely at home under the supervision of trained health care staff. Our study provides a framework for other centres to selectively transition patients from traditional infusion centres to alternative destinations such as home based. With further safety studies other infusion therapies could potentially be transitioned safety to be delivered at home at the convenience of the patient.

    猜你喜歡
    大伙
    巨大的回報
    哪里哪里?
    太陽感冒了
    老人的尊嚴
    上海故事(2018年4期)2018-07-09 18:44:58
    改啰唆
    愛你(2017年20期)2017-11-24 16:26:38
    冬天是個調(diào)皮的孩子
    官員講大白話,大伙愛聽
    紅土地(2016年11期)2017-01-15 13:46:36
    腳下生風(fēng)的磊編
    意林(2015年20期)2015-10-21 11:21:08
    生日福利
    趕時間的后果
    解放軍生活(2013年9期)2013-04-29 08:52:02
    禁无遮挡网站| 免费观看a级毛片全部| 国产av不卡久久| 日日摸夜夜添夜夜爱| 麻豆乱淫一区二区| 国产亚洲精品av在线| 三级国产精品欧美在线观看| 久久99热这里只有精品18| 最近中文字幕高清免费大全6| 成年人午夜在线观看视频 | 99re6热这里在线精品视频| 亚洲激情五月婷婷啪啪| 国产高清国产精品国产三级 | 啦啦啦中文免费视频观看日本| 能在线免费观看的黄片| 久久这里有精品视频免费| 国产成人精品久久久久久| 菩萨蛮人人尽说江南好唐韦庄| 91在线精品国自产拍蜜月| 国产乱来视频区| 久久久精品免费免费高清| 肉色欧美久久久久久久蜜桃 | 亚洲欧美日韩卡通动漫| 欧美成人精品欧美一级黄| 日韩成人伦理影院| av网站免费在线观看视频 | 欧美高清性xxxxhd video| 伊人久久精品亚洲午夜| 男人舔女人下体高潮全视频| 精品久久久久久久末码| 观看免费一级毛片| 人妻制服诱惑在线中文字幕| av国产免费在线观看| 久久综合国产亚洲精品| 嘟嘟电影网在线观看| 久久亚洲国产成人精品v| 22中文网久久字幕| 免费大片18禁| 成人亚洲精品av一区二区| 久久精品国产亚洲av涩爱| 2022亚洲国产成人精品| 青青草视频在线视频观看| 久久久久性生活片| 国产精品99久久久久久久久| 精华霜和精华液先用哪个| 青青草视频在线视频观看| 韩国高清视频一区二区三区| 欧美激情久久久久久爽电影| 99热网站在线观看| 男人爽女人下面视频在线观看| 亚洲av成人精品一区久久| 高清午夜精品一区二区三区| 亚洲国产av新网站| 国模一区二区三区四区视频| 日韩视频在线欧美| 久久精品人妻少妇| 视频中文字幕在线观看| 亚洲图色成人| 免费观看在线日韩| 色吧在线观看| 精品人妻熟女av久视频| 91精品一卡2卡3卡4卡| 亚洲av国产av综合av卡| 美女xxoo啪啪120秒动态图| 韩国av在线不卡| 亚洲精华国产精华液的使用体验| 亚洲精品日韩av片在线观看| 欧美成人一区二区免费高清观看| 国产色婷婷99| 国产极品天堂在线| 69人妻影院| 亚洲精品中文字幕在线视频 | 国产精品一及| 性色avwww在线观看| 中文在线观看免费www的网站| 国产精品久久久久久久电影| 久久久久久国产a免费观看| 乱系列少妇在线播放| 美女被艹到高潮喷水动态| 中文天堂在线官网| 男女边吃奶边做爰视频| 亚洲成人一二三区av| 国产探花极品一区二区| av国产免费在线观看| 69av精品久久久久久| 久久精品国产亚洲av天美| 老司机影院毛片| 国产精品久久久久久精品电影| 一本久久精品| 99热这里只有是精品50| 欧美zozozo另类| 日韩亚洲欧美综合| 日韩在线高清观看一区二区三区| 久久精品久久久久久噜噜老黄| 91久久精品国产一区二区成人| 狠狠精品人妻久久久久久综合| 伦理电影大哥的女人| 国产伦精品一区二区三区视频9| 色播亚洲综合网| 欧美成人午夜免费资源| 美女脱内裤让男人舔精品视频| 亚洲av免费在线观看| 亚洲av免费高清在线观看| 成人综合一区亚洲| 亚洲精品,欧美精品| 超碰av人人做人人爽久久| 晚上一个人看的免费电影| 国内精品一区二区在线观看| 一级毛片 在线播放| 大片免费播放器 马上看| 国产在视频线在精品| 亚洲电影在线观看av| 国产av不卡久久| 99热6这里只有精品| 中文资源天堂在线| 99久久精品热视频| 日韩 亚洲 欧美在线| 免费av观看视频| 亚洲欧美日韩无卡精品| 国产在视频线精品| 国产精品人妻久久久久久| 国产精品无大码| 久久99热这里只频精品6学生| 国产精品蜜桃在线观看| 免费观看在线日韩| 国产精品三级大全| 久久久久久久国产电影| 亚洲成色77777| 99久久中文字幕三级久久日本| 99久国产av精品国产电影| 亚洲在线自拍视频| 亚洲自拍偷在线| 91久久精品国产一区二区成人| 老师上课跳d突然被开到最大视频| 成年女人看的毛片在线观看| 久久综合国产亚洲精品| 男女那种视频在线观看| av在线观看视频网站免费| 校园人妻丝袜中文字幕| 日本一本二区三区精品| 国产三级在线视频| 亚洲婷婷狠狠爱综合网| 午夜免费男女啪啪视频观看| 久久久成人免费电影| 国产亚洲av嫩草精品影院| 亚洲丝袜综合中文字幕| 少妇被粗大猛烈的视频| 国产精品久久视频播放| 人人妻人人看人人澡| 国产 一区精品| 久久午夜福利片| 中文字幕久久专区| 男人舔奶头视频| 国产黄片视频在线免费观看| 欧美一级a爱片免费观看看| 麻豆久久精品国产亚洲av| 精品一区在线观看国产| 天堂影院成人在线观看| 在线观看av片永久免费下载| 卡戴珊不雅视频在线播放| 亚洲av成人精品一区久久| 婷婷色麻豆天堂久久| 91在线精品国自产拍蜜月| 高清毛片免费看| 国产成人精品久久久久久| 精品一区在线观看国产| 精品人妻一区二区三区麻豆| av在线观看视频网站免费| 日日干狠狠操夜夜爽| 国产在视频线在精品| 亚洲第一区二区三区不卡| 精品久久国产蜜桃| 亚洲av在线观看美女高潮| av在线蜜桃| 听说在线观看完整版免费高清| 午夜精品国产一区二区电影 | 免费观看av网站的网址| 精品一区在线观看国产| 乱码一卡2卡4卡精品| 22中文网久久字幕| 午夜福利在线观看吧| 亚洲丝袜综合中文字幕| 精品一区二区免费观看| 国产精品国产三级国产专区5o| 亚洲色图av天堂| 亚州av有码| 色视频www国产| 欧美日韩综合久久久久久| 床上黄色一级片| 亚洲精品456在线播放app| 国产精品1区2区在线观看.| 精品久久久久久久久av| 99久国产av精品| 欧美日韩一区二区视频在线观看视频在线 | 午夜福利高清视频| 日日摸夜夜添夜夜爱| 中文字幕久久专区| 久久久久精品久久久久真实原创| 亚洲欧美一区二区三区国产| 久久久久久久久久人人人人人人| 欧美性感艳星| 成年女人在线观看亚洲视频 | 69人妻影院| 一级爰片在线观看| 少妇丰满av| 成人性生交大片免费视频hd| 插逼视频在线观看| 一夜夜www| 国产精品麻豆人妻色哟哟久久 | 蜜桃久久精品国产亚洲av| 国产高潮美女av| 亚洲精品久久午夜乱码| 日韩欧美一区视频在线观看 | 高清毛片免费看| 国内少妇人妻偷人精品xxx网站| 免费观看无遮挡的男女| 午夜视频国产福利| 丰满人妻一区二区三区视频av| 久久久久性生活片| 永久免费av网站大全| 女人十人毛片免费观看3o分钟| 亚洲三级黄色毛片| 又大又黄又爽视频免费| 久久人人爽人人片av| av天堂中文字幕网| 天美传媒精品一区二区| 少妇的逼水好多| 日韩不卡一区二区三区视频在线| 秋霞在线观看毛片| 人妻夜夜爽99麻豆av| 欧美激情在线99| 日韩电影二区| 日韩欧美三级三区| 99热这里只有精品一区| 免费看a级黄色片| 精品久久久精品久久久| 成人高潮视频无遮挡免费网站| 国产男人的电影天堂91| 极品少妇高潮喷水抽搐| 美女主播在线视频| a级毛色黄片| 国产午夜福利久久久久久| 免费观看性生交大片5| 精品久久久噜噜| 看非洲黑人一级黄片| 亚洲欧美中文字幕日韩二区| 精品国产一区二区三区久久久樱花 | 久久久欧美国产精品| www.色视频.com| 久久久久性生活片| 22中文网久久字幕| 精品欧美国产一区二区三| 色综合色国产| 一个人免费在线观看电影| 国产 一区 欧美 日韩| 久久99蜜桃精品久久| 日韩亚洲欧美综合| 夜夜看夜夜爽夜夜摸| 一个人免费在线观看电影| 免费人成在线观看视频色| 日韩制服骚丝袜av| 中文字幕亚洲精品专区| 亚洲成人精品中文字幕电影| 久久精品国产亚洲网站| 天天躁夜夜躁狠狠久久av| 午夜福利在线观看吧| 亚洲,欧美,日韩| 亚洲av成人av| 在线观看人妻少妇| 日韩不卡一区二区三区视频在线| 晚上一个人看的免费电影| 男女边摸边吃奶| 男插女下体视频免费在线播放| 91狼人影院| 国产成人精品婷婷| 国产大屁股一区二区在线视频| 国产真实伦视频高清在线观看| 国产精品一区www在线观看| 人人妻人人澡人人爽人人夜夜 | 天堂网av新在线| 久久这里只有精品中国| 狠狠精品人妻久久久久久综合| 日产精品乱码卡一卡2卡三| 精品欧美国产一区二区三| 国产精品不卡视频一区二区| a级毛片免费高清观看在线播放| 久久精品国产亚洲av天美| 国产精品无大码| 在现免费观看毛片| 一级毛片黄色毛片免费观看视频| 成人无遮挡网站| 久久鲁丝午夜福利片| 97在线视频观看| 在线观看人妻少妇| 97人妻精品一区二区三区麻豆| 亚洲成人久久爱视频| 夜夜看夜夜爽夜夜摸| 午夜福利视频精品| 国产精品一区二区三区四区免费观看| 久久综合国产亚洲精品| 国产伦理片在线播放av一区| 91久久精品国产一区二区三区| 亚洲人成网站高清观看| 日本wwww免费看| 亚洲一区高清亚洲精品| 亚洲精品久久久久久婷婷小说| 大香蕉97超碰在线| 99视频精品全部免费 在线| 久久99热这里只频精品6学生| kizo精华| 狂野欧美激情性xxxx在线观看| 国产综合懂色| 亚洲综合色惰| 中文在线观看免费www的网站| 免费播放大片免费观看视频在线观看| 亚洲精品国产av蜜桃| 黄片无遮挡物在线观看| 51国产日韩欧美| 免费观看在线日韩| 亚洲最大成人手机在线| 国产精品久久久久久久电影| 男插女下体视频免费在线播放| 女人久久www免费人成看片| 18禁在线播放成人免费| 国产成人一区二区在线| 亚洲av电影在线观看一区二区三区 | 久久精品熟女亚洲av麻豆精品 | 如何舔出高潮| 欧美日韩精品成人综合77777| 亚洲图色成人| 亚洲国产精品专区欧美| 色尼玛亚洲综合影院| av免费观看日本| 久久精品久久久久久久性| 亚洲激情五月婷婷啪啪| 午夜爱爱视频在线播放| 中文字幕av成人在线电影| 好男人在线观看高清免费视频| 国产精品久久久久久久电影| 2021少妇久久久久久久久久久| 美女脱内裤让男人舔精品视频| av卡一久久| 人妻制服诱惑在线中文字幕| 一二三四中文在线观看免费高清| 免费无遮挡裸体视频| 嫩草影院新地址| 中国美白少妇内射xxxbb| 久久久久久久午夜电影| 国产成人午夜福利电影在线观看| 亚洲最大成人av| 久久久精品免费免费高清| 久久久国产一区二区| 亚洲人成网站高清观看| 亚洲自偷自拍三级| 夜夜爽夜夜爽视频| 国产黄a三级三级三级人| 免费观看精品视频网站| 久久久久久国产a免费观看| 亚洲丝袜综合中文字幕| 91久久精品国产一区二区三区| 日韩欧美一区视频在线观看 | 精品久久久噜噜| 亚州av有码| 国产高清三级在线| 高清av免费在线| 精品国内亚洲2022精品成人| 97在线视频观看| 久久久精品免费免费高清| 麻豆国产97在线/欧美| 久久精品熟女亚洲av麻豆精品 | av线在线观看网站| 亚洲欧洲国产日韩| 中文字幕人妻熟人妻熟丝袜美| 亚洲美女视频黄频| 伊人久久国产一区二区| 国产精品一及| 亚洲三级黄色毛片| av一本久久久久| 精品久久久久久久人妻蜜臀av| 国产精品三级大全| 中文资源天堂在线| 最近中文字幕高清免费大全6| 天天一区二区日本电影三级| 亚洲国产精品成人综合色| 欧美激情久久久久久爽电影| 久久午夜福利片| 最近中文字幕2019免费版| 能在线免费看毛片的网站| 大陆偷拍与自拍| 一本久久精品| 日韩欧美 国产精品| 国产精品一区www在线观看| 久久热精品热| 国产精品一二三区在线看| 国产午夜精品久久久久久一区二区三区| 美女高潮的动态| 国产真实伦视频高清在线观看| 国产69精品久久久久777片| 国产一区二区三区av在线| 91精品国产九色| 精华霜和精华液先用哪个| 中文字幕亚洲精品专区| 免费av毛片视频| 国产 一区 欧美 日韩| 亚洲18禁久久av| 欧美潮喷喷水| 综合色av麻豆| 国产精品99久久久久久久久| 男女视频在线观看网站免费| av.在线天堂| 国产精品嫩草影院av在线观看| av在线蜜桃| 亚洲欧美一区二区三区国产| 91aial.com中文字幕在线观看| 国产一级毛片在线| 亚洲av成人精品一二三区| 在线观看免费高清a一片| av天堂中文字幕网| 国产在视频线精品| 久久久久久九九精品二区国产| 在线免费观看不下载黄p国产| 久久热精品热| 免费看av在线观看网站| 婷婷六月久久综合丁香| 久久久a久久爽久久v久久| 国产亚洲91精品色在线| 亚洲精品一二三| 搡老妇女老女人老熟妇| 亚洲成人av在线免费| 亚洲精品国产av成人精品| 我的老师免费观看完整版| 国产精品久久久久久精品电影小说 | 久久久a久久爽久久v久久| 五月玫瑰六月丁香| 免费av观看视频| 天美传媒精品一区二区| 久久久久久久久久人人人人人人| 一本一本综合久久| 国产爱豆传媒在线观看| 建设人人有责人人尽责人人享有的 | 久久草成人影院| 成人国产麻豆网| 国产 一区 欧美 日韩| 九色成人免费人妻av| 亚洲欧美成人精品一区二区| 亚洲欧美日韩卡通动漫| 人体艺术视频欧美日本| 简卡轻食公司| 亚洲欧美精品专区久久| 成年av动漫网址| 国产精品国产三级国产av玫瑰| 成人欧美大片| 搡老妇女老女人老熟妇| 国产老妇女一区| 麻豆成人午夜福利视频| 街头女战士在线观看网站| 嘟嘟电影网在线观看| 久久99热这里只有精品18| 亚洲在线观看片| 色综合站精品国产| 久久精品国产亚洲av涩爱| 97在线视频观看| 亚洲无线观看免费| 日韩av在线大香蕉| 国内精品美女久久久久久| 秋霞在线观看毛片| 又大又黄又爽视频免费| 黄色欧美视频在线观看| 美女xxoo啪啪120秒动态图| 国产精品.久久久| 性色avwww在线观看| av网站免费在线观看视频 | 成人毛片60女人毛片免费| 久久精品国产亚洲网站| 亚洲av成人精品一二三区| 国产成人精品一,二区| 成人特级av手机在线观看| 国产成人freesex在线| 成人无遮挡网站| 国产精品综合久久久久久久免费| 亚洲精品456在线播放app| www.色视频.com| 可以在线观看毛片的网站| 国产精品精品国产色婷婷| 免费无遮挡裸体视频| 99久国产av精品国产电影| 亚洲av国产av综合av卡| 高清毛片免费看| 又粗又硬又长又爽又黄的视频| 在线播放无遮挡| 一二三四中文在线观看免费高清| 亚洲av日韩在线播放| 国产亚洲一区二区精品| 久久久久久久久大av| a级一级毛片免费在线观看| 久久99热这里只频精品6学生| 国产av码专区亚洲av| 人妻少妇偷人精品九色| 欧美日韩在线观看h| 精品亚洲乱码少妇综合久久| 久久久久久国产a免费观看| 免费看光身美女| 美女cb高潮喷水在线观看| 久久精品人妻少妇| 蜜桃久久精品国产亚洲av| 一边亲一边摸免费视频| 少妇熟女aⅴ在线视频| 国产亚洲精品久久久com| 免费看a级黄色片| 伊人久久国产一区二区| 男女国产视频网站| 亚洲av二区三区四区| 简卡轻食公司| 国产不卡一卡二| 欧美97在线视频| 观看美女的网站| 高清午夜精品一区二区三区| 亚洲欧美日韩无卡精品| 观看免费一级毛片| 欧美一区二区亚洲| 肉色欧美久久久久久久蜜桃 | 小蜜桃在线观看免费完整版高清| 卡戴珊不雅视频在线播放| 亚洲精品aⅴ在线观看| 超碰97精品在线观看| 亚洲av男天堂| 日日摸夜夜添夜夜添av毛片| 欧美xxxx黑人xx丫x性爽| 精品人妻偷拍中文字幕| 中文字幕亚洲精品专区| 亚洲内射少妇av| 日韩,欧美,国产一区二区三区| 美女cb高潮喷水在线观看| 国产黄频视频在线观看| 国产在视频线在精品| 激情 狠狠 欧美| 亚洲成人av在线免费| 久久人人爽人人片av| 亚洲国产精品专区欧美| 97超碰精品成人国产| 97热精品久久久久久| 日日啪夜夜撸| 国产乱人偷精品视频| 久久久精品欧美日韩精品| 成人亚洲欧美一区二区av| 99热全是精品| 七月丁香在线播放| 国产伦在线观看视频一区| 精品久久久精品久久久| 国产精品福利在线免费观看| 十八禁国产超污无遮挡网站| 日韩成人av中文字幕在线观看| 欧美xxⅹ黑人| 欧美日韩亚洲高清精品| 午夜激情久久久久久久| 少妇高潮的动态图| 国产人妻一区二区三区在| 日韩精品有码人妻一区| 亚洲人成网站在线观看播放| 亚洲精品影视一区二区三区av| 男女啪啪激烈高潮av片| 亚洲av在线观看美女高潮| 国产亚洲最大av| av福利片在线观看| 99热这里只有是精品在线观看| 丰满人妻一区二区三区视频av| 欧美人与善性xxx| 国产精品嫩草影院av在线观看| 3wmmmm亚洲av在线观看| 国产激情偷乱视频一区二区| 一级毛片久久久久久久久女| av在线蜜桃| 亚洲久久久久久中文字幕| 男女国产视频网站| 插逼视频在线观看| 国产一级毛片在线| 麻豆国产97在线/欧美| .国产精品久久| 久久99热6这里只有精品| 亚洲自偷自拍三级| 九草在线视频观看| 欧美xxxx性猛交bbbb| 菩萨蛮人人尽说江南好唐韦庄| 久久亚洲国产成人精品v| 亚洲四区av| eeuss影院久久| 小蜜桃在线观看免费完整版高清| 精品久久久精品久久久| 国产 一区精品| av专区在线播放| 97热精品久久久久久| 国产一区二区三区av在线| 久久精品熟女亚洲av麻豆精品 | 国产伦在线观看视频一区| 亚洲精品日本国产第一区| 最新中文字幕久久久久| 午夜视频国产福利| 亚洲综合精品二区| 日韩欧美精品v在线| 啦啦啦韩国在线观看视频| 久久午夜福利片| 国产真实伦视频高清在线观看| 成人一区二区视频在线观看| 91精品伊人久久大香线蕉| 午夜福利在线在线| 天堂网av新在线| 亚洲精品影视一区二区三区av| 国产三级在线视频| 免费人成在线观看视频色| 97热精品久久久久久| 国产精品福利在线免费观看| 日韩电影二区| 最后的刺客免费高清国语| 深夜a级毛片| 国产在线男女|